A Precision-Built T-Cell Therapy Targets the B Cells Behind Myasthenia Gravis
Myasthenia gravis is an autoimmune disorder in which the immune system attacks the body’s own machinery for controlling muscle movement. In the most common form of the disease, antibodies directed against the acetylcholine receptor, or AChR, interfere with communication between nerves and muscles. These antibodies can block the receptor, accelerate its removal from the muscle-cell surface, and activate complement proteins that damage the neuromuscular junction. The result is fluctuating weakness that often affects the eyes, face, swallowing muscles, limbs, and respiratory muscles. A new study published in Nature Communications describes an engineered cellular strategy designed to remove the B cells responsible for producing these disease-driving antibodies, rather than relying only on broad immune suppression.
The research, led by Nils von Wardenburg, Giulia Spagni, Sarah M. Reincke, and colleagues, focuses on a technology known as a chimeric autoantibody receptor, or CAAR. CAARs are synthetic receptors placed on the surface of T cells. Unlike conventional chimeric antigen receptors, which are generally designed to recognize proteins displayed on tumor cells, a CAAR can be built from part of the very self-protein targeted by an autoimmune response. In this case, the researchers used an acetylcholine receptor-based recognition system to guide therapeutic T cells toward B cells whose surface antibodies recognize AChR. The approach effectively turns the pathogenic B-cell receptor into a molecular address label.
The central challenge in autoimmune disease is eliminating harmful immune cells without destroying the entire healthy B-cell population. Conventional B-cell-depleting treatments can reduce autoantibody production, but they also remove many B cells that are not involved in the disease. That broad effect may increase susceptibility to infection and can leave patients dependent on repeated treatment. AChR-specific CAAR T cells are intended to be more selective. When their engineered receptor encounters an AChR-specific B-cell receptor, the therapeutic T cell can become activated and attack that particular B cell. B cells lacking the relevant autoreactivity should be largely ignored, preserving more of the normal immune repertoire.
The study advances this concept by developing bispecific CAAR T cells. The term “bispecific” indicates that the engineered T cells are designed to recognize two related molecular features rather than relying on a single recognition interaction. Such a design may improve the ability to capture the diverse AChR-reactive B-cell clones that can arise during myasthenia gravis. Autoantibodies are not always identical: they may bind different regions, or epitopes, of the same antigen, and disease-associated B cells can carry distinct antibody sequences. By broadening target recognition while retaining antigen specificity, the researchers sought to create a cellular therapy capable of addressing a wider fraction of the pathogenic population.
In experimental systems modeling myasthenia gravis, the engineered cells eliminated AChR-specific B cells. This is a crucial distinction from simply neutralizing circulating antibodies. Antibodies can persist in the bloodstream for a period of time even after their producing cells have been removed, and long-lived plasma cells may continue secreting them. A cellular therapy aimed at the B-cell compartment is therefore intended to interrupt the source of new autoantibody production. The findings indicate that the bispecific CAAR design could recognize and destroy disease-relevant B cells in models while offering a more focused alternative to indiscriminate immune depletion.
The biological logic behind the treatment is based on the normal behavior of cytotoxic T cells. Once a CAAR T cell binds its target, signaling domains inside the synthetic receptor transmit activation signals through the T cell. The activated cell can then release cytotoxic granules containing perforin and granzymes, trigger programmed death in the target, and produce inflammatory signaling molecules that support the immune response. For autoimmune applications, however, the threshold for activation must be carefully controlled. An overly sensitive receptor could attack cells that carry related but harmless antibodies, whereas a weak receptor might fail to remove enough pathogenic clones. The bispecific architecture is therefore not merely an engineering variation; it is an attempt to balance breadth, potency, and precision.
The work is part of a broader movement to adapt CAR T-cell technology beyond cancer. In oncology, CAR T cells are used to recognize malignant cells bearing defined surface markers. In autoimmune disease, the target is more difficult because the harmful cells may be rare, distributed across tissues, and intermixed with healthy immune cells that share many of the same biological features. Autoantigen-based CAAR T cells offer a different strategy: instead of identifying a generic B-cell marker, they exploit the antigen specificity of the B-cell receptor itself. If the concept translates to patients, it could provide a way to attack the immune clones that initiate or sustain disease while minimizing the collateral loss of protective immunity.
The findings also highlight the complexity of treating antibody-mediated neurological disorders. Myasthenia gravis is not caused by a single uniform immune mechanism in every patient. Some individuals produce antibodies against AChR, while others have antibodies against proteins such as MuSK or LRP4. The therapy described in this study is specifically directed at AChR-reactive B cells and would not automatically address other antibody-defined subtypes. In addition, the persistence of plasma cells, the movement of immune cells between blood and tissues, and the possibility of disease relapse all require careful investigation. A successful treatment would need to demonstrate not only target-cell elimination in models but also durable reduction of pathogenic antibodies and meaningful recovery of neuromuscular function.
As with all preclinical cellular therapies, substantial hurdles remain before clinical testing can establish safety and efficacy in people. Researchers will need to evaluate manufacturing consistency, the persistence and distribution of the engineered T cells, the risk of excessive immune activation, and the possibility of unintended recognition of normal tissues. The treatment’s effects on infection defense and vaccination responses will also be important, particularly if the cells remain active for months or years. Investigators must further determine whether the therapy can reach relevant B-cell populations in lymphoid organs and other anatomical sites, and whether its activity can be controlled if adverse effects occur.
The significance of the study lies in its precision-driven vision for autoimmune medicine. Rather than suppressing the immune system broadly, bispecific CAAR T cells are designed to identify and remove the B-cell clones that recognize a disease-causing self-antigen. In myasthenia gravis models, that strategy successfully focused cellular cytotoxicity on AChR-specific B cells, providing a proof of concept for a highly selective treatment platform. The next stage will be translating the molecular design into a clinically practical therapy and determining whether targeted immune-cell deletion can deliver lasting relief without compromising essential immune protection. If those challenges can be solved, the approach could help redefine how researchers treat antibody-mediated diseases—not by silencing immunity everywhere, but by removing the precise cells that have turned against the body.
Subject of Research: Bispecific chimeric autoantibody receptor T cells targeting acetylcholine receptor-specific B cells in myasthenia gravis models
Article Title: Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models
Article References: von Wardenburg, N., Spagni, G., Reincke, S.M. et al. Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models. Nat Commun 17, 8730 (2026). https://doi.org/10.1038/s41467-026-76750-7
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41467-026-76750-7
Keywords: myasthenia gravis, autoimmune disease, acetylcholine receptor, B cells, CAAR T cells, CAR T-cell therapy, bispecific receptors, autoantibodies, precision immunotherapy, neuromuscular junction
